Gilead Sciences wins FDA backing for weekly HIV pill, Cantor sticks to Overweight call on the shares

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-22, 17:11.

Gilead Sciences (US3755581036) has secured a key U.S. regulatory milestone for its HIV prevention franchise. The NASDAQ-listed biotech reports that the Food and Drug Administration has accepted its supplemental new drug application for Yeztugo 300-mg tablets as a once-weekly oral pre-exposure prophylaxis option, according to recent company and analyst commentary.Zacks analyst blog on the FDA filing

What the FDA move changes

Gilead said the FDA has set a target action date of February 2, 2027 for the Yeztugo once-weekly oral PrEP filing, backed by Phase 3 data in diverse populations at risk of HIV infection.Zacks analyst blog on the FDA filing The tablet would complement the existing twice-yearly injectable lenacapavir regimen that is already approved in the United States for HIV-1 prevention.

Beyond HIV, Gilead recently highlighted results from collaboration trials with Merck where an islatravir/lenacapavir combination produced positive outcomes in HIV treatment, while the EVOKE-03 study in non-small cell lung cancer delivered negative data, underscoring the mixed nature of its oncology pipeline progress.Investing.com summary of pipeline updates and trials

Cantor Fitzgerald stays bullish on Gilead

On Wall Street, Cantor Fitzgerald has reiterated its Overweight rating on Gilead with a price target of 155 U.S. dollars, positioning the stock above the current NASDAQ level.Cantor Fitzgerald reiteration reported by Investing.com The firm cites a market capitalization of roughly 153.7 billion dollars and a dividend yield around 2.6 percent as key valuation markers.

Cantor also points to recent prescription trends for Yeztugo, noting that total prescriptions fell about 2 percent week-over-week to approximately 1,722, while injectable Yeztugo prescriptions stayed broadly flat at roughly 980 over the same period.Investing.com data on Yeztugo prescriptions and rating rationale For income investors, analysts highlight that Gilead has raised its dividend for 11 consecutive years, underlining management’s focus on shareholder returns.Investing.com commentary on dividend history

The medicines that drive revenues

Gilead’s cash flows are anchored by antiviral therapies, notably the HIV portfolio and hepatitis C legacy brands, with key products including Biktarvy for HIV treatment and lenacapavir-based Yeztugo for prevention. The company also markets the antiviral remdesivir, which it recently donated in more than 2,000 vials to Uganda as part of an Ebola outbreak response.Investing.com coverage of remdesivir donation

Where the shares trade now

Gilead Sciences shares (US3755581036) recently changed hands on the NASDAQ at around 123.76 U.S. dollars, based on a delayed quote from June 22, 2026, 01:19 Eastern Time, implying a market capitalization of roughly 153.7 billion dollars and placing the stock in the S&P 500 healthcare cohort.Davy price snapshot for Gilead

This article is for informational purposes only and does not constitute investment advice, an offer or a solicitation to buy or sell any securities. Figures and dates are based on publicly available sources believed to be reliable but are not guaranteed for accuracy or completeness.